BERLIN — Pharmaceutical company BioNTech and its U.S. partner Pfizer say they will provide 100 million more doses of their coronavirus vaccine to the European Union this year.
The two companies said Monday that the 27-nation group’s executive Commission exercised an option to purchase the additional doses, bringing the total number of shots to be delivered to the EU in 2021 to 600 million.
The announcement offers a much-needed boost to the EU’s sluggish and much-criticized vaccine rollout.
Sean Marett, the chief business officer of BioNTech, said deliveries of the company’s mRNA-based vaccine this year will cover two-thirds of the EU population.
The bloc has so far administered about 105 million shots to its population of some 450 million. Most vaccines require two shots to provide full immunization.
GENEVA (AP) — The World Health Organization said Friday that COVID-19 no longer qualifies as a global emergency, marking a symbolic end to the devastating coronavirus pandemic that triggered once-unthinkable lockdowns, upended economies and killed millions of people worldwide.
FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.
Explore articles from the past and connect to your heritage!
Discover the benefits of a subscription including access to exclusive content, events, and more!
Have an idea for a story, or know of an event we should cover? We want to hear about it!
The National Herald is the paper of record of the Greek Diaspora community. Through independent journalism, we bring news to generations of Greek-Americans, with stories on the individual, community and international level. Visit and support our 106 year-old sister publication Εθνικός Κήρυξ.
To purchase a gift subscription, please log out of your account, and purchase the subscription with a new email ID.
Sign up to receive our daily email news briefing.
Sign up for a subscription to The National Herald,
starting as low as $1/week.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
We use cookies on our site to personalize your experience, bring you the most relevant content, show you the most useful ads, and to help report any issues with our site. You can update your preferences at any time by visiting preferences. By selecting Accept, you consent to our use of cookies. To learn more about how your data is used, visit our cookie policy.
$1.07 USD
